NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein. CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.

加利福尼亚州纽波特海滩，2024年1月2日（环球通讯社）--私人生物技术公司Healis Therapeutics今天宣布，它已经与CKD Bio Corporation（A063160.KS）签订了CKDB-501（一种神经调节剂BoNT/a蛋白）的供应协议。CKD Bio是位于韩国首尔的崇坤党集团的子公司。

Healis Therapeutics intends to develop CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). Healis plans to enter clinical trials in the U.S. and other countries. “We are excited to work with CKD Bio, a global leader in biologics, on a collaboration to develop CKDB-501 for MDD and PTSD” said Dr.

Healis Therapeutics打算开发CKDB-501治疗重度抑郁症（MDD）和创伤后应激障碍（PTSD）。Healis计划在美国和其他国家进行临床试验。“我们很高兴与生物制剂领域的全球领导者CKD Bio合作，共同开发用于MDD和PTSD的CKDB-501”，Dr。

Eric Finzi, Co-Founder of Healis, who started the field of BoNT/A for depression research. Worldwide, approximately 280 million patients experience Major Depressive Disorder (MDD) annually, according to the World Health Organization (WHO). In the U.S. alone, 22 million patients suffer from MDD and 20 million from PTSD, annually, according to data collected by the National Institutes of Mental Health and Department of Veterans Affairs.

埃里克·芬奇（EricFinzi）是Healis的联合创始人，他开创了抑郁症研究的BoNT/A领域。据世界卫生组织（WHO）统计，全球每年约有2.8亿患者患有重度抑郁症（MDD）。根据美国国立精神卫生研究院和退伍军人事务部收集的数据，仅在美国，每年就有2200万MDD患者和2000万PTSD患者。

“Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans” said Sebastian De Beurs, Co-Founder of Healis. “This planned clinical development represents the largest patient population and market opportunity of any therapeutic indication in the history of BoNT/A,” De Beurs said.

Healis联合创始人塞巴斯蒂安·德·比尔斯（SebastianDeBeurs）表示：“我们与CKD Bio在这项新协议上的合作有朝一日可能会影响4200多万美国人。”。De Beurs说：“这项计划的临床开发代表了BoNT/A历史上最大的患者人数和任何治疗适应症的市场机会。”。

Ten randomized controlled trials conducted in 5 countries to date have shown promising early results on glabellar Botulinum Toxin Type A (BoNT/A) treatments for Major Depressive Disorder (MDD). “We hope this partnership will accelerate the development of BoNT/A as a potential on-label treatment available to millions of MDD and PTSD patients worldwide” said Dr.

迄今为止，在5个国家进行的10项随机对照试验显示，A型小脑肉毒杆菌毒素（BoNT/A）治疗重度抑郁症（MDD）的早期结果令人鼓舞。“我们希望这种伙伴关系将加速BoNT/A的发展，作为全球数百万MDD和PTSD患者可用的潜在标签上治疗，”Dr。

Finzi. A.

芬兹。A.